Daiichi Sankyo And Yakult File For Additional Approval Of Irinotecan For Childhood Malignant Solid Tumors
This article was originally published in PharmAsia News
Daiichi Sankyo and Yakult announced Nov. 9 they have each filed for an additional indication of the cancer drug irinotecan (Daiichi’s Topotecin, Yakult’s Campto) for the treatment of pediatric malignant solid tumors.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.